Addition of EBT to brachytherapy does not produce superior PFS results

October 03, 2016

BOSTON, MA -- NRG Oncology researchers reported that adding external radiation therapy to standard brachytherapy did not improve progression-free survival for men with intermediate-risk prostate cancer. The initial primary endpoint results of NRG-RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-Risk Prostatic Carcinoma were presented at today's plenary session of the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts.

"NRG-RTOG 0232 was initiated to determine if external beam therapy with brachytherapy would be a potentially more effective means to treat prostate cancer and prolong progression-free survival," says Bradley R. Prestidge, MD, of the DePaul Medical Center at the Bon Secours Cancer Institute and lead author of NRG-RTOG 0232.

NRG-RTOG 0232 randomized 588 men with prostate cancer, clinical stage T1c-T2b and either a Gleason Score (GS) of 2-6/PSA 10-20 or GS 7/PSA <10, to external beam radiation therapy plus brachytherapy (n=292) vs. brachytherapy alone (n=296). The study was designed to test for a 10% increase in 5-year progression-free survival (PFS) for the external beam plus brachytherapy arm.

Results from NRG-RTOG 0232 indicated there were no significant differences in baseline characteristics between arms. At the fifth of five planned interim analyses, based on the required 443 patients for that analysis, five-year PFS was 85% for the external beam radiation therapy plus brachytherapy arm and 86% for the brachytherapy only arm. Toxicity in both groups was limited, but there were significantly fewer late effects, mostly genitourinary, noted in the brachytherapy alone arm. Based on this final interim analysis, the NRG Oncology Data Monitoring Committee recommended reporting the results early.

"The results of this study are a testament to the efforts of NRG Oncology, which continues to define and strive for a new standard of care for patients with prostate cancer," stated Walter J. Curran, Jr., MD, an NRG Oncology Group Chair and Executive Director of the Winship Cancer Institute of Emory University.
-end-
NRG-RTOG 0232 was funded by grants from the National Cancer Institute.

http://www.nrgoncology.org

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group. The research organization seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

NRG Oncology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.